SEC Filings
SiriusXM Picks Anjali Sud For CEO As Paid-Subscriber Challenges Await Its Next Leader
The Tubi chief will succeed Jennifer Witz in January, with a $2.6 million salary and a $10 million sign-on stock award.
SEC Filings
The Tubi chief will succeed Jennifer Witz in January, with a $2.6 million salary and a $10 million sign-on stock award.
SEC Filings
The financing carries a 9.35% minimum interest rate and pledges substantially all assets, including intellectual property.
SEC Filings
AN2 expects its funds to last into 2029, with enrollment in its global blood-cancer trial expected by year-end.
SEC Filings
The company plans a myasthenia gravis trial in mid-2027, pending regulatory feedback, as it expands beyond thyroid eye disease.
SEC Filings
Nine-month product sales reached $143.6 million, while the company plans to seek approval for patients not previously treated with BCG.
SEC Filings
The relutrigine team is fully hired, with FDA decisions targeted for December and January.
SEC Filings
The China study treated 12 patients, with interim results supporting Cullinan’s development plans beyond lupus.
SEC Filings
LISRAYA’s launch raised selling costs, while arthritis, eye-disease and lung-disease trials advanced.
SEC Filings
Insurance access expanded, while commercialization and research spending climbed and operating cash use increased.
SEC Filings
Sherif’s director awards include options on 88,000 shares and restricted stock units covering 28,000 shares.
SEC Filings
Partner milestones lifted revenue, while Editas expects its cash to fund operations beyond planned 2027 clinical results.
SEC Filings
Treatment is complete for all 108 late-stage trial participants, and Aura expects its funding to last into the first half of 2029.